

# Identification and Localization of an Actin-binding Motif That Is Unique to the Epsilon Isoform of Protein Kinase C and Participates in the Regulation of Synaptic Function

Rytis Prekeris, Mark W. Mayhew,\* J. Bryan Cooper,\* and David M. Terrian

Department of Anatomy and Cell Biology, \*Department of Biology, East Carolina University School of Medicine, Greenville, North Carolina 27858

**Abstract.** Individual isoforms of the protein kinase C (PKC) family of kinases may have assumed distinct responsibilities for the control of complex and diverse cellular functions. In this study, we show that an isoform specific interaction between PKC $\epsilon$  and filamentous actin may serve as a necessary prelude to the enhancement of glutamate exocytosis from nerve terminals. Using a combination of cosedimentation, overlay, and direct binding assays, we demonstrate that filamentous actin is a principal anchoring protein for PKC $\epsilon$  within intact nerve endings. The unusual stability and direct nature of this physical interaction indicate that actin filaments represent a new class of PKC-binding protein. The binding of PKC $\epsilon$  to actin required that the kinase be activated, presumably to expose a cryptic

binding site that we have identified and shown to be located between the first and second cysteine-rich regions within the regulatory domain of only this individual isoform of PKC. Arachidonic acid (AA) synergistically interacted with diacylglycerol to stimulate actin binding to PKC $\epsilon$ . Once established, this protein-protein interaction securely anchored PKC $\epsilon$  to the cytoskeletal matrix while also serving as a chaperone that maintained the kinase in a catalytically active conformation. Thus, actin appears to be a bifunctional anchoring protein that is specific for the PKC $\epsilon$  isoform. The assembly of this isoform-specific signaling complex appears to play a primary role in the PKC-dependent facilitation of glutamate exocytosis.

**E**VOOLUTION has conserved a fundamental mechanism that ensures the sorting and fusion of secretory vesicles upon their delivery to appropriate destinations along the secretory pathway. In many eukaryotes, however, alternative pathways have emerged in which vesicle delivery and fusion have become rigorously regulated events that are capable of manifesting use-dependent variations in the probability of their occurrence. Glutamate exocytosis is a particularly striking example of a secretory event that, in presynaptic nerve terminals, has acquired a highly evolved mechanism for regulating the efficiency of excitatory synaptic transmission. Moreover, it has been established that use-dependent changes in the reliability (Stevens and Wang, 1994) and extent (Schulz et al., 1994) of glutamate exocytosis directly participate in certain forms of synaptic plasticity.

Studies from many laboratories suggest that a conditional relationship may exist between the efficiency of glutamate release and the activity of presynaptic protein

kinase C (PKC).<sup>1</sup> These studies have shown that the Ca<sup>2+</sup>-dependent release of glutamate is significantly enhanced in the presence of phorbol esters, which activate most isoforms of PKC, and that this effect can be blocked by inhibitors of serine/threonine kinase activity (Yamamoto et al., 1987; Madison et al., 1991; Huang et al., 1992). Confirmation of these results in preparations of isolated nerve endings (synaptosomes) established a presynaptic locus for the PKC-dependent enhancement of sustained glutamate release and provided a simple system in which to identify the molecular components of the PKC signaling pathway that are capable of facilitating synaptic vesicle recruitment during bouts of intense synaptic activity (Terrian et al., 1993). The PKC family includes at least 11 different isoforms that possess different requirements for activation and are widely believed to have assumed distinctive cellular responsibilities (for reviews see Nishizuka, 1992; Hug

Address all correspondence to David M. Terrian, Department of Anatomy and Cell Biology, East Carolina University School of Medicine, Greenville, NC 27858-4354. Tel.: (919) 816-3247. Fax: (919) 816-2850.

1. *Abbreviations used in this paper:* AA, arachidonic acid; GAP-43, growth-associated protein; GS1-406, truncated recombinant gelsolin; OAG, oleyl-acetyl-glycerol; P<sub>3</sub>, hippocampal mossy fiber-enriched synaptosomal fraction; PDBu, phorbol 12,13-dibutyrate; PS, phosphatidylserine; PKC, protein kinase C; RACK, receptors for activated C kinase; TX100, Triton X-100.

and Sarre, 1993; Dekker and Parker, 1994). Much research on this growing family of protein kinases has concentrated on the individual functions of these isoforms. The PKC gene family is divided into three subfamilies; the  $\text{Ca}^{2+}$ -dependent or conventional ( $\text{PKC}\alpha$ ,  $\beta$ ,  $\gamma$ ,  $\epsilon$ , and  $\zeta$ ), the  $\text{Ca}^{2+}$ -independent or novel ( $\text{PKC}\delta$ ,  $\epsilon$ ,  $\eta$ ,  $\theta$ , and  $\mu$ ), and phorbol ester-insensitive or atypical subfamilies ( $\text{PKC}\zeta$  and  $\iota/\lambda$ ). The synaptosomal preparation used in our previous studies has been shown to contain at least five of the known isoforms of PKC ( $\text{PKC}\alpha$ ,  $\beta$ ,  $\gamma$ ,  $\epsilon$ , and  $\zeta$ ) and eight unidentified endogenous substrates for this kinase (Terrian et al., 1993; Terrian, 1995; Terrian and Ways, 1995). The coexistence of various PKC isoforms within an assortment of isolated nerve endings and their relatively minor differences in substrate specificity (Hug and Sarre, 1993; Dekker and Parker, 1994) raises the question of how heterogeneous and isoform-specific functions might be achieved within the same presynaptic terminal.

One mechanism that is likely to contribute to the operational diversity of PKC isoforms involves the differential colocalization of an activated PKC isoform with its endogenous protein substrates (for review see Mochly-Rosen, 1995). Indeed, although phorbol esters activate the majority of PKC isoforms, many of the isoforms which are present within a given cell translocate to different subcellular domains (Kiley et al., 1992; Disatnik et al., 1994; Staudinger et al., 1995). Cell specific patterns of redistribution may also be observed for an individual PKC isoform, depending on the complement of isoform specific PKC-binding proteins that are expressed by the cell. These intracellular PKC-binding proteins, sometimes referred to as "receptors for activated C kinase" (RACKs; Mochly-Rosen et al., 1991) or as proteins that interact with C-kinase (PICKs; Staudinger et al., 1995), are believed to determine the topogenic fate of the PKC isoforms by differentially anchoring the PKCs to specific cellular compartments. Several PKC-binding proteins have now been cloned and shown to preferentially interact with certain isoforms of PKC (Chapline et al., 1993; Ron et al., 1994). However, no PKC-binding protein known to us has been shown to be specifically paired with an individual isoform of PKC. Such absolute targeting specificity would require that the anchoring protein contain a binding site that is uniquely matched to an isoform-specific localization signal.

In the present study, we have examined the potential involvement of individual PKC isoforms in the enhancement of sustained glutamate exocytosis, the pattern of their subcellular redistribution, the determinants of isoform specific targeting within presynaptic terminals, and the conditions required for their constitutive activation. The results revealed that at least one requirement for the enhancement of sustained glutamate exocytosis may be the positioning of activated  $\text{PKC}\epsilon$  within the cytoskeletal matrix of presynaptic terminals. Four independent lines of evidence indicated that the  $\text{PKC}\epsilon$  isoform was selectively anchored to this complex aggregate of insoluble proteins through an unusually secure and direct protein-protein interaction with filamentous actin. Using purified actin and recombinant  $\text{PKC}\epsilon$ , it was confirmed that complementary domains within these proteins physically interacted with one another through the formation of a salt-bridge that was stable at physiological ionic strength. In addition, an actin-

binding motif was identified in the regulatory domain of  $\text{PKC}\epsilon$  that appeared to be conformationally hidden when the kinase was inactive and that is not conserved in any other known members of the PKC family. These observations support the notion that  $\text{PKC}\epsilon$  contains an actin-binding sequence that assigns a distinct responsibility to this individual kinase in mediating the PKC-dependent replenishment of synaptic vesicles during repetitive bouts of presynaptic depolarization.

## Materials and Methods

### *In Vivo Destruction of Dentate Granule Cells*

Male Sprague-Dawley rats were anesthetized and positioned in a Kopf stereotaxic apparatus. Two unilateral intradentate injections of colchicine (3.5  $\mu\text{g}$ ) were delivered, using the coordinates described previously (Conner-Kerr et al., 1993). Contralateral sham injections were also delivered to each animal. After a postinjection period of 10 d, animals were sacrificed, hippocampi were removed, and synaptosomes were prepared (see below) using either the sham- or colchicine-injected hippocampi as starting tissue. Colchicine selectively destroyed the rat, but not guinea pig, dentate granule cell-mossy fiber pathway under these conditions (Conner-Kerr et al., 1993).

### *Synaptosomal Preparation*

Male Hartley guinea pigs were used in all experiments that did not require the use of colchicine-induced lesions. Animals were decapitated, the hippocampi removed and manually disrupted in a 0.3 M sucrose medium containing 1 mM  $\text{MgSO}_4$  and 15 mM sodium *N*-tris (hydroxymethyl) methyl-2-aminoethane-sulfonic acid (pH 7.4) at 0–5°C, using custom-machined Dounce type homogenizers (Terrian et al., 1988). The differential centrifugation procedures used to prepare hippocampal mossy fiber-enriched fractions ( $\text{P}_3$ ) have been described in detail (Terrian et al., 1988). An identical protocol was used to isolate  $\text{P}_3$  fractions from sham- or colchicine-injected rat hippocampi. Synaptosomal pellets were resuspended in an oxygenated,  $\text{Ca}^{2+}$ -free, Krebs-bicarbonate medium (Terrian, 1995).

### *Phorbol Ester Preincubation Conditions*

Synaptosomes were incubated for 5 min at 30°C before introducing  $\text{CaCl}_2$  (1.4 mM) to the medium and incubating for an additional 15 min. Aliquots of the synaptosomal suspension were then transferred to separate tubes and incubated at 30°C for 10 min in the presence of the PKC activator, 4 $\beta$ -phorbol 12,13-dibutyrate (4 $\beta$ -PDBu; 1  $\mu\text{M}$ ), or an equimolar concentration of the inactive phorbol ester, 4 $\alpha$ -PDBu. Where specified, intact synaptosomes were exposed to 1  $\mu\text{M}$  cytochalasin D, 1  $\mu\text{M}$  staurosporine, or 100  $\mu\text{M}$  sphingosine 20 min before the introduction of phorbol esters.

### *Superfusion Procedures*

Aliquots of the synaptosomal suspension were layered onto parallel superfusion columns (Terrian, 1995) and superfused (0.5 ml/min) at room temperature with an oxygenated Krebs-bicarbonate medium containing 1.4 mM  $\text{CaCl}_2$ . The relatively hydrophilic phorbol ester, PDBu, is completely washed out of intact synaptosomes within a 28-min exposure to these superfusion conditions (Terrian et al., 1993). Beginning at 27 min, four sequential 5-min superfusate fractions were collected and prepared for fluorometric assay of glutamate by measuring the production of NADH by glutamic acid dehydrogenase (Terrian et al., 1988). Glutamate release was evoked by the introduction of 35 mM KCl to the superfusion medium, in equimolar substitution for NaCl (Terrian and Ways, 1995).

### *Cellular Fractionation*

Synaptosomes were disrupted by sonication in 20 mM Tris-HCl (pH 7.4) containing 10 mM EDTA, 2 mM EGTA, 100 mM  $\beta$ -glycerophosphate, 0.05 mg/ml phenylmethylsulfonyl fluoride, 0.1 mg/ml aprotinin, 1 mg/ml leupeptin, 2  $\mu\text{M}$  pepstatin, and 0.1 mg/ml ovalbumin. Cytosolic fractions were obtained by centrifugation (78,000 *g* for 20 min at 4°C). Using a recombinant  $\text{PKC}\epsilon$  standard, it was determined that the resulting supernatant contained a weight ratio of 7 ng  $\text{PKC}\epsilon$ /1  $\mu\text{g}$  cytosolic protein. The

particulate fractions (0.5 mg protein) were extracted with 250  $\mu$ l of a 1% (vol/vol) Triton X-100 (TX100) solution at 4°C for 20 min, unless specified otherwise. The TX100-soluble and -insoluble fractions were then separated by sedimentation (20 min at 78,000 g). In some experiments, the TX100-insoluble material was reextracted using a variety of additional solubilization protocols for 30 min at 4°C (see Table I). All TX100-insoluble fractions were finally resuspended in a cytoskeletal buffer that consisted of 125 mM Tris-HCl (pH 6.8), 1.25% SDS, 3 mM EDTA, 0.25 M sucrose, 10% glycerol, 1% 2-mercaptoethanol, and protease inhibitors (see above).

### Cosedimentation Assays

The  $\text{Ca}^{2+}$ -independent, *in vitro*, binding of native PKCs to the 1% TX100-insoluble fraction was analyzed using a modification of the cosedimentation assay described by Mochly-Rosen et al. (1991). In brief, 100  $\mu$ g of 1% TX100-insoluble synaptosomal protein was resuspended in 50  $\mu$ l of 20 mM Tris-HCl (pH 7.4) containing 10 mM EDTA, 2 mM EGTA, 100 mM  $\beta$ -glycerophosphate, and 0.05 mg/ml PMSF, and preincubated for 30 min at 30°C. Where indicated, the 1% TX100-insoluble fraction was pretreated with trypsin (Mochly-Rosen et al., 1991) or 25  $\mu$ g of recombinant gelsolin GS1-406 (Sun et al., 1994). Sonicated phosphatidylserine (PS) liposomes (20  $\mu$ g/ml) and  $\text{CaCl}_2$  (1 mM) were also added to the reaction medium, where specified. Native synaptosomal cytosol (150  $\mu$ g protein) was then introduced, in the presence of the indicated amount of either 4 $\alpha$ -PDBu or 4 $\beta$ -PDBu, to a final volume of 120  $\mu$ l incubation medium. TX100-insoluble aggregates were sedimented and subjected to immunoblot analysis as previously described (Terrian et al., 1991), using antipeptide antisera specific for the  $\alpha$ ,  $\beta_{II}$ ,  $\epsilon$ , and  $\zeta$  isoforms of PKC. These antisera recognize proteins of the predicted molecular mass for their respective isoforms. The specificity of the detected proteins was confirmed by the ability of the immunizing peptide to abolish detection of these bands (Ways et al., 1991; Terrian et al., 1993). Antibody-reactive bands were visualized with either peroxidase-labeled secondary antibodies and enhanced chemiluminescence or  $^{125}\text{I}$ -protein A. Densitometric analysis of the autoradiograms was performed to quantify changes in the relative content of PKC.

### Actin-binding Assays

Varying amounts of purified rabbit skeletal muscle actin were preincubated for 30 min at room temperature, in 150  $\mu$ l of 4 mM Tris-HCl (pH 7.5) containing 10  $\mu$ M  $\text{CaCl}_2$ , 30 mM KCl, 120 mM potassium propionate, 1 mM  $\text{MgCl}_2$ , 150  $\mu$ M ATP, and 100  $\mu$ M  $\text{ZnCl}_2$ , before the addition of 50  $\mu$ g synaptosomal cytosol (350 ng PKC $\epsilon$ ). The volume of the incubation mixture was adjusted to 220  $\mu$ l and samples were incubated for 30 min at 30°C in the presence of either 1  $\mu$ M 4 $\alpha$ -PDBu or 4 $\beta$ -PDBu. Where indicated, varying amounts of synthetic peptides (LKKQET, PKC $\alpha_{19-31}$ , or annexin I $_{338-345}$ ) were added to the incubation medium at the same time as PDBu. Mixtures of purified actin and native cytosol were also incubated in the presence of 1  $\mu$ M oleyl-acetyl-glycerol (OAG), with or without varying concentrations of arachidonic acid (AA). Filamentous actin was sedimented (78,000 g for 30 min at 4°C) and resuspended in cytoskeletal buffer before SDS-PAGE and immunoblot analysis. In an additional series of experiments, purified and denatured human recombinant PKC $\alpha$ ,  $\delta$ , and  $\epsilon$  (100 ng of each) were individually coinubated with purified actin, in the absence of 4 $\beta$ -PDBu and in the absence or presence of the synthetic hexapeptide, LKKQET (80  $\mu$ M). The volume was adjusted to 220  $\mu$ l and samples were incubated for 30 min at room temperature before sedimenting the filamentous actin, as above, and resuspending the pellets in cytoskeletal buffer for immunoblot analysis. The final actin concentration was 5  $\mu$ M in each assay, the minimum required for reproducible sedimentation of actin pellets.

### Overlay Assays

Denatured, 1% TX100-insoluble, synaptosomal proteins that are capable of binding to native PKC under *in vitro* conditions were analyzed using a modification of the overlay assay described by Jaken and colleagues (Liao et al., 1994). TX100-insoluble protein (150  $\mu$ g) was denatured and separated by SDS-PAGE and transferred to nitrocellulose membranes that were incubated for 3 h at 4°C with a Tris-buffered saline (TBS) that contained 5% milk powder. The TBS consisted of 10 mM Tris-HCl (pH 7.4) and 150 mM NaCl. Nitrocellulose filter-bound proteins were then washed

twice with TBS and incubated for 1 h at room temperature in TBS containing 10  $\mu$ g/ml cytosolic protein, 10 mg/ml bovine serum albumin, 1 mM EGTA, 10  $\mu$ g/ml leupeptin, 10  $\mu$ g/ml aprotinin, and 1  $\mu$ M 4 $\beta$ -PDBu. After two more washes with phosphate-buffered saline, the membranes were probed using either anti-PKC $\alpha$ ,  $\epsilon$ ,  $\zeta$ , or anti- $\beta$  actin antisera.

### In Vitro Protein Phosphorylation

Synaptosomal 1% TX100-insoluble protein (150  $\mu$ g) was resuspended in 200  $\mu$ l of Tris-HCl (pH 7.4) that contained native cytosolic protein (80  $\mu$ g), 0.1 mM EGTA, and 1  $\mu$ M 4 $\alpha$ -PDBu or 4 $\beta$ -PDBu. After a 5-min incubation at room temperature, insoluble aggregates were sedimented (13,500 g for 5 min). Where specified, these pellets were washed three times with 200  $\mu$ l of 20 mM Tris-HCl (pH 7.4). The final pellets were all resuspended in 185  $\mu$ l of 20 mM Tris-HCl (pH 7.4) containing 0.1 mM EGTA. The assay of *in vitro* phosphotransferase activity was initiated by adding 15  $\mu$ l of 20 mM Tris-HCl containing 180 mM  $\text{MgCl}_2$ , 12  $\mu$ M ATP, and [ $\gamma$ - $^{32}\text{P}$ ]ATP (0.26 mCi/ml). Samples were incubated for 5 min at 30°C and sedimented as before. Pellets were washed twice with 200  $\mu$ l of 20 mM Tris-HCl (pH 7.4) and resuspended in cytoskeletal buffer before SDS-PAGE using 5–15% linear gradient gels and autoradiographic analysis.



### Miscellaneous

Treatment effects were evaluated by determining the significance of the difference between means using a paired Student's *t* test. SDS-PAGE using 5–15% linear gradient gels was performed as described in the Hoefer Protein Electrophoresis Applications Guide. A recombinant protein containing the amino-terminal half of gelsolin (GS1-406) was provided by Dr. Helen L. Yin, University of Texas Southwestern Medical Center (Dallas, TX). Antipeptide antisera against PKC $\alpha$ ,  $\beta_{II}$ ,  $\gamma$ ,  $\delta$ ,  $\epsilon$ ,  $\zeta$ ,  $\eta$ , and  $\theta$  were provided by Dr. D. Kirk Ways, East Carolina University School of Medicine (Greenville, NC). Purified actin was provided by Dr. Joseph M. Chalovich, East Carolina University School of Medicine. Purified human recombinant PKC standards ( $\alpha$ ,  $\delta$ , and  $\epsilon$ ) were obtained from Oxford Biomedical Research, Inc. Drugs were obtained from Sigma Chem. Co. (St. Louis, MO) and antibodies to  $\beta$ -actin and growth-associated protein (GAP-43) were obtained from Sigma Immunochemicals. Anti-synaptophysin and anti-GAP-43 antibodies were obtained from Boehringer Mannheim Biochemical (St. Louis, MO). Synthetic peptides homologous to PKC $\epsilon_{223-228}$  (LKKQET) and annexin I $_{338-345}$  (KILVALCG) were obtained from Bio-Synthesis, Inc (Lewisville, TX). The pseudosubstrate peptide, PKC $\alpha_{19-31}$ , was obtained from LC Laboratories.

### Results

#### Presynaptic Localization of PKC $\alpha$ , PKC $\epsilon$ , and PKC $\zeta$

We have taken advantage of the fact that colchicine selectively destroys the rat dentate granule cell – mossy fiber pathway *in vivo* to identify proteins that are endogenous to hippocampal mossy fiber nerve endings. Comparisons of the P<sub>3</sub> fractions that were prepared from ipsilateral (lesioned) and contralateral (sham-injected) hippocampi indicated that destruction of the mossy fibers reduced the content of synaptophysin and GAP-43; proteins that are localized to the presynaptic terminals of all hippocampal neurons, by 93% and 63%, respectively (Fig. 1 A). In contrast, the synaptosomal content of PKC $\beta_{II}$  and  $\gamma$  was unaltered by colchicine (Fig. 1 B), indicating that mossy fiber nerve endings are unlikely to be the source of these PKC isoforms. The antipeptide antiserum against PKC $\eta$  did not detect any proteins of the predicted molecular mass in the P<sub>3</sub> fraction. Although a ~116-kD immunoreactive protein that may represent a high molecular size isoform of PKC $\eta$  (Sublette et al., 1993) was observed, colchicine appeared to increase rather than reduce the content of this unidentified protein (Fig. 1 B). Colchicine-induced lesions also increased the content of PKC $\delta$  in the P<sub>3</sub> fraction. An antipeptide antiserum against PKC $\theta$  detected no proteins in

**A****B**


**Figure 1.** Presynaptic localization of PKC isoforms by deletion analysis. (A) Effects of selectively removing mossy fiber nerve endings from hippocampal P<sub>3</sub> subcellular fractions, using in vivo intradentate injections of colchicine, on the relative content of two presynaptic marker proteins, synaptophysin, and GAP-43. Hippocampal homogenates (H) are shown for reference. (B) Effects of colchicine-induced lesions on the recovery of various PKC isoforms (PKCα, β<sub>II</sub>, γ, δ, ε, ζ, and η) in the rat hippocampal P<sub>3</sub> subcellular fraction. "ND" means not detected. Equal amounts of protein were applied to the adjacent lanes of each gel shown in A and B, above. Representative blots are shown from two (PKCδ) or three independent experiments and data are reported as the means ± SEM.

either the P<sub>3</sub> fraction or whole rat brain standard (data not shown). Only PKCα, ε, and ζ were significantly decreased as a result of this lesion (Fig. 1 B). These observations indicate that hippocampal mossy fiber nerve endings contain at least one representative from each of the three subfamilies of PKC.

#### **4β-PDBu Selectively Promotes the Chelator-Stable Association of PKCε with a TX100-resistant Fraction That Is Maintained, In Situ, in the Absence of 4β-PDBu**

Once established, the 4β-PDBu-induced enhancement of glutamate exocytosis has been shown to become stabilized in intact synaptosomes and independent of phorbol esters, while remaining sensitive to PKC inhibitors (Terrian et al., 1993; Terrian and Ways, 1995). In an attempt to determine whether this persistent facilitation of release was mediated by either reversible or irreversible hydrophobic interac-

tions of PKC with membrane lipids (Bazzi and Nelsestuen, 1988; Kazanietz et al., 1992), translocation assays were performed using intact synaptosomes. Both mechanisms are thought to contribute to the constitutive activation of PKC. The principal criteria used to distinguish between the reversibly bound and "membrane-inserted" forms of PKC are that, in the later case, the solubility of the enzyme is reduced when intact cells are treated with phorbol esters and that the association of PKC with the particulate fraction becomes independent of phorbol esters and resists extraction with EGTA, but not the detergent TX100 (Bazzi and Nelsestuen, 1988; Kazanietz et al., 1992). In addition, the enhancement of glutamate release does not stabilize during an acute (1 min) exposure to 4β-PDBu, but persists when synaptosomes are pretreated for at least 10 min with 4β-PDBu, and then washed to remove this phorbol ester (Terrian et al., 1993). Using these criteria, synaptosomes were incubated for 45 min in the presence of either the in-



**Figure 2.** In situ translocation of endogenous PKC $\alpha$ ,  $\epsilon$ , and  $\zeta$ . Effects of  $4\beta$ -PDBu on the subcellular distribution of PKC $\zeta$  (A), PKC $\alpha$  (B), and PKC $\epsilon$  (C). Intact synaptosomes were incubated for 45 min and exposed to  $1\ \mu\text{M}$   $4\beta$ -PDBu during the final period of incubation, for the time indicated. Fractions obtained from synaptosomes that were incubated for 45 min with the inactive phorbol ester,  $4\alpha$ -PDBu, are indicated as a 0-min exposure. Synaptosomes were then disrupted and separated into cytosolic and particulate fractions. Particulate fractions were extracted using 0.1% TX100 and further separated into TX100-soluble and TX100-resistant fractions. Immunoblot analysis was used to determine the effect of  $4\beta$ -PDBu on the solubility of PKC $\alpha$ ,  $\epsilon$ , and  $\zeta$ . The stability of in situ PKC interactions were examined by removing  $4\beta$ -PDBu from intact synaptosomes after a 10-min exposure (condition 10W). Amounts of protein loaded into adjacent lanes of a given immunoblot were equivalent, but varied between fractions and isoforms. These immunoblots are representative of the results obtained in three independent experiments using 0.1% TX100. At a final concentration of 1.0% TX100, the same results were obtained in two additional experiments.

active phorbol ester,  $4\alpha$ -PDBu, or  $4\beta$ -PDBu for 1, 10, or 45 min and sonicated in the presence of a buffer that contained 2.4 mM EGTA. The solubility of PKC isoforms, following their  $4\beta$ -PDBu-dependent redistribution, was initially analyzed by extracting the particulate protein with 0.1% TX100, at a detergent to protein ratio of 5:1. Cytosolic, 0.1% TX100-soluble, and 0.1% TX100-resistant fractions were prepared from whole synaptosomal lysates. Where specified, PDBu was washed out of the intact synaptosomes before cellular fractionation. No effect of  $4\beta$ -PDBu on the distribution of PKC $\zeta$  was detected under these conditions (Fig. 2 A), indicating that the disruption of intact synaptosomes itself was not responsible for an artifactual redistribution of the other, phorbol ester-responsive, isoforms of PKC. Like PKC $\zeta$ , PKC $\delta$  also did not respond to  $4\beta$ -PDBu treatment (data not shown). The content of cytosolic PKC $\alpha$ ,  $\beta_{II}$ ,  $\gamma$ , and  $\epsilon$  decreased within 1 min of treatment with  $4\beta$ -PDBu. However, this decrease in PKC $\alpha$ ,  $\beta_{II}$ , and  $\gamma$  solubility was completely reversed by removal of  $4\beta$ -PDBu (Fig. 2 and data not shown). PKC $\epsilon$  was the sole member of the PKC family that could be localized to mossy

fiber terminals (Fig. 1), maintained a persistent association with a particulate fraction in the absence of  $4\beta$ -PDBu in situ, and resisted extraction with 2.4 mM EGTA in vitro (Fig. 2C). In contrast to the membrane-inserted form of PKC, however, PKC $\epsilon$  could not be extracted from the particulate fraction using 0.1% TX100 (Fig. 2).  $4\beta$ -PDBu also significantly decreased the solubility of PKC $\epsilon$  when extractions were performed using a final concentration of 1% TX100 (see below). These observations raised the question of whether or not the  $4\beta$ -PDBu-induced decrease in PKC $\epsilon$  solubility resulted from a direct interaction between the kinase and membrane bilayer (Bazzi and Nelsestuen, 1988) or the unexpected formation of a secure PKC $\epsilon$ -cytoskeletal complex (Wolf and Sahyoun, 1986).

**Activated PKC $\epsilon$  Becomes Insoluble Due to Saturable, Ionic, Protein-Protein Interactions That Are Independent of Calcium or Phosphatidylserine**

To determine the nature of PKC $\epsilon$  binding that is established under in situ conditions, intact synaptosomes were

**Table I. Solubilization of PKC $\epsilon$  after In Situ Targeting to the Synaptosomal 1% TX100-Insoluble Matrix by 4 $\beta$ -PDBu**

| Reextraction                                    | Insoluble protein* | Insoluble PKC $\epsilon$ † |
|-------------------------------------------------|--------------------|----------------------------|
|                                                 | (Total)<br>%       | (4 $\alpha$ -PDBu)<br>%    |
| None                                            | 44                 | 174                        |
| Octyl Glucoside                                 | 7                  | 179                        |
| (NH <sub>4</sub> ) <sub>2</sub> SO <sub>4</sub> | 14                 | 108                        |
| NaCl                                            | 13                 | 86                         |
| pH 12                                           | 6                  | 109                        |

Intact synaptosomes were treated with either 1  $\mu$ M 4 $\alpha$ -PDBu or 4 $\beta$ -PDBu. Particulate fractions were obtained by centrifugation of synaptosomal lysates and initially extracted with 1% TX100. All subsequent extractions from this 1% TX100-insoluble aggregate were performed at 4°C for 30 min. Octyl glucoside was used at a final concentration of 100 mM, (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub> at 250 mM, and NaCl at 3 M concentrations. Alkali conditions were established using a 0.1-M Na<sub>2</sub>CO<sub>3</sub> buffer. 4 $\alpha$ -PDBu-treated synaptosomes were used as a paired control.


\* Insoluble protein is expressed as the percent of total synaptosomal protein that resisted extraction using 1% TX100 alone (None) or with an additional reextraction by the methods specified.

† Insoluble PKC $\epsilon$  represents the relative amount of PKC $\epsilon$  that resisted extraction, using the method specified. Aliquots from the same synaptosomal suspension were exposed to either 4 $\alpha$ - or 4 $\beta$ -PDBu, extracted with 1% TX100, and reextracted in an identical manner. Values are expressed as the percent of insoluble PKC $\epsilon$  recovered in the paired 4 $\alpha$ -PDBu control for each treatment condition.

treated with either 1  $\mu$ M 4 $\alpha$ -PDBu or 4 $\beta$ -PDBu and the soluble and insoluble forms of PKC $\epsilon$  were separated using 1% TX100. The 1% TX100-insoluble material was then either analyzed directly or treated with a variety of alternative solubilization buffers that contained both EDTA and EGTA. After treatment with 4 $\alpha$ -PDBu, 44% of the total synaptosomal protein and ~10% of the total endogenous PKC $\epsilon$  was recovered in the 1% TX100-insoluble fraction (Table I). Thus, the majority of this enzyme appeared to be either cytosolic or membrane associated under basal conditions. 4 $\beta$ -PDBu redistributed an additional 7% of the total PKC $\epsilon$  to the synaptic skeleton (173% of the corresponding 4 $\alpha$ -PDBu control, Table I), where this kinase now resisted solubilization by 1% TX100. To further challenge the ability of PKC $\epsilon$  to resist solubilization by non-


ionic detergents, samples of the TX100-insoluble material were reextracted using octyl glucoside. Octyl glucoside is a considerably more stringent detergent than TX100 and displaces even detergent-resistant glycosylphosphatidylinositol anchored proteins from cell membranes (Brown and Rose, 1992). After reextracting the 1% TX100-insoluble material with 100 mM octyl glucoside, at a detergent to protein ratio of ~6:1, only 7% of the total synaptosomal protein remained insoluble (Table I). Western blots confirmed that the presynaptic integral membrane protein, synaptophysin, was completely solubilized by this combination of detergent extractions (data not shown). However, no PKC $\epsilon$  was recovered in the additional protein that had been solubilized by octyl glucoside (Table I). Thus, the 4 $\beta$ -PDBu-stabilized binding of PKC $\epsilon$  was clearly not dependent on the direct interaction of this kinase with membrane lipids. In contrast, PKC $\epsilon$  was completely displaced from the 1% TX100-insoluble matrix when the ionic strength (3 M NaCl) or alkalinity (pH 12) of the extraction buffer was increased (Table I), indicating that the in situ binding of PKC $\epsilon$  may be mediated by electrostatic interactions between two or more proteins. The fact that Na<sub>2</sub>CO<sub>3</sub> buffers titrated to a pH of 11 failed to interfere with the binding of PKC $\epsilon$  suggested that these ionic interactions were unusually stable (data not shown).

Specific protein interactions are both saturable and concentration dependent. After the coinubation of native cytosolic and 1% TX100-insoluble fractions in the presence of 4 $\beta$ -PDBu, neither PKC $\alpha$  nor PKC $\zeta$  cosedimented with the insoluble fraction (data not shown). As in the previous experiment, however, 4 $\beta$ -PDBu significantly increased the association of PKC $\epsilon$  with the 1% TX100-insoluble fraction (Fig. 3 A). PKC $\epsilon$  binding was saturable and strictly dependent on the concentration of soluble PKC $\epsilon$  that was included in the incubation mixture (Fig. 3 B). To evaluate whether PS and Ca<sup>2+</sup> mediate the interaction of PKC $\epsilon$  with an unidentified PS-binding protein (Wolf and Sahyoun, 1986; Liao et al., 1994), sonicated PS liposomes and



**Figure 3.** In vitro binding of native, cytosolic, PKC $\epsilon$  to a 1% TX100 insoluble aggregate of synaptosomal proteins. (A) Conditions required for in vitro binding of PKC $\epsilon$ . Cytosol (150  $\mu$ g) and 1% TX100-insoluble fractions (100  $\mu$ g) were coinubated in the absence (lanes 1 and 2) or presence of the PKC activators, 1.4 mM CaCl<sub>2</sub> (lanes 4, 6, and 7), 20 mg/ml PS (lanes 3, 4, 6, and 7) and 1  $\mu$ M 4 $\beta$ -PDBu (lanes 5, 6, and 7). In lane 7, the 1% TX100-insoluble fraction was exposed to mild trypsinization before the addition of a trypsin inhibitor and cytosol, accord-

ing to the method of Mochly-Rosen et al. (1991). The same results were obtained in three independent experiments. (B) Cytosolic PKC $\epsilon$  binding to the 1% TX100-insoluble fraction (50  $\mu$ g protein) at different concentrations of cytosol. CaCl<sub>2</sub>, PS, and 4 $\beta$ -PDBu were present at all points, in the concentrations specified above. Data are the means  $\pm$  SEM of the values obtained in three independent experiments.



**Figure 4.** Rate of dissociation for PKC $\epsilon$  binding in the absence of 4 $\beta$ -PDBu. PKC $\epsilon$  binding to a 1% TX100 insoluble aggregate of synaptosomal proteins was established under in vitro conditions by incubation with the native cytosol in the presence of 1  $\mu$ M 4 $\beta$ -PDBu. Three washes were performed to remove >90% of the bound 4 $\beta$ -PDBu, this was confirmed using [ $^3$ H]4 $\beta$ -PDBu (inset). After incubation in the absence of phorbol ester for the time specified, soluble and insoluble forms of PKC $\epsilon$  were separated and immunoblot analyses were performed to determine the relative amount of PKC $\epsilon$  that remained insoluble. Data are the means  $\pm$  SEM of the values from three independent experiments. The turnover constant for bound PKC $\epsilon$  was estimated by performing a curve fit on the mean values using Sigma Plot Scientific Graphing Software 2.0 (Jandel Scientific, Inc.).

Ca $^{2+}$  were added to the in vitro cosedimentation assay mixture. As shown in Fig. 3 A, PKC $\epsilon$  binding was increased by 4 $\beta$ -PDBu (lane 5) and abolished by pretreating the 1% TX100-insoluble fraction with trypsin (lane 7). However, PS had no effect on the solubility of PKC $\epsilon$ , in either the absence or presence of Ca $^{2+}$  (Fig. 3 A, lanes 3 and 4), and the combination of PS and Ca $^{2+}$  did not augment the 4 $\beta$ -PDBu-induced binding of PKC $\epsilon$  (Fig. 3 A, lane 6). These data demonstrate that PKC $\epsilon$  binds to the detergent-insoluble fraction via direct protein-protein interactions that are not dependent on the formation of a "PS-Ca $^{2+}$  bridge" (Wolf and Sahyoun, 1986; Liao et al., 1994).

It has previously been demonstrated that the 4 $\beta$ -PDBu-dependent enhancement of glutamate exocytosis is dependent on the presence of an intact actin-based cytoskeleton (Terrian and Ways, 1995). Therefore, we tested the ability of 250 mM (NH $_4$ ) $_2$ SO $_4$  to solubilize PKC $\epsilon$  because of its reported efficiency in extracting the filamentous, actin-based, cytoskeleton from cellular lysates (Fey et al., 1984). (NH $_4$ ) $_2$ SO $_4$  almost completely solubilized the PKC $\epsilon$  (Table I).


#### **PKC $\epsilon$ Remains Insoluble in the Absence of 4 $\beta$ -PDBu and Native Cytosol**

To determine how tightly PKC $\epsilon$  associates with the detergent-insoluble components of nerve endings, we examined the kinetics for the dissociation of this complex. Synaptosomal cytosolic and 1% TX100-insoluble fractions were isolated and then reintroduced to one another, under in

vitro conditions, in the presence of either 1  $\mu$ M 4 $\alpha$ -PDBu or 4 $\beta$ -PDBu, 10 mM EDTA, and 2 mM EGTA. Essentially all of the soluble PDBu, and >90% of the bound PDBu, was then removed by washing the TX100-insoluble aggregate three times (Fig. 4, inset). The washed pellets were next resuspended in a Tris buffer and aliquots of this suspension were removed at specified times to determine the amount of PKC $\epsilon$  that remained bound to the TX100-insoluble fraction. Data were analyzed using the following equation:  $B(t) = B_0 \times e^{-(k/t)}$ , where  $B(t)$  was the amount of PKC $\epsilon$  bound at any given time point,  $B_0$  was the maximal amount of bound PKC $\epsilon$ ,  $k$  was the turnover constant ( $1/\tau$ ), and  $t$  was time. It was observed that, in the absence of 4 $\beta$ -PDBu and in the presence of chelators, PKC $\epsilon$  and the TX100-insoluble fraction remained tightly associated with one another and exhibited a turnover constant of 0.0134 ( $\tau = 75$  min; Fig. 4).

#### **PKC $\epsilon$ Remains Catalytically Active within the Presynaptic Cytoskeletal Matrix after the Removal of Phorbol Ester**

Phosphotransferase activity is not required for PKC $\epsilon$  to bind the detergent-insoluble proteins. Indeed, all in vitro cosedimentation assays were performed in the absence of ATP and under conditions which do not support this activity. Thus, an alternative mechanism must account for the ability of 4 $\beta$ -PDBu to stabilize the repositioning of PKC $\epsilon$ . It is well established that when phorbol esters bind to the cysteine-rich regions of PKCs the cryptic pseudosubstrate and substrate-binding domains of these enzymes dissociate and become exposed (for review see Hug and Sarre, 1993). This observation raised the possibility that PKC $\epsilon$  could only interact with anchoring proteins when the enzyme assumed an active conformation. An important functional consequence of such a requirement would be that PKC $\epsilon$  remained constitutively active while it was anchored to native PKC $\epsilon$ -binding proteins. The fact that PKC $\epsilon$  was the only endogenous isoform that bound to the detergent-



**Figure 5.** In vitro phosphorylation of native TX100-insoluble proteins by bound PKC $\epsilon$ . Soluble PKC $\epsilon$  was co-incubated with 1% TX100-insoluble protein in the presence of either the inactive phorbol ester, 1  $\mu$ M 4 $\alpha$ -PDBu (lanes 1 and 3), or 1  $\mu$ M 4 $\beta$ -PDBu (lanes 2 and 4). Insoluble proteins were then sedimented and the absence of bound PKC $\alpha$  and  $\zeta$  was confirmed by immunoblot analysis of the unwashed pellets (data not shown). The phosphotransferase reaction was initiated by adding

[ $\gamma^{32}$ P]ATP in the absence (lanes 3 and 4) or presence (lanes 1 and 2) of 1  $\mu$ M PDBu. Insoluble pellets were washed three times to remove PDBu (lanes 3 and 4). PKC $\epsilon$ -dependent phosphotransferase activity was estimated by measuring changes in the phosphorylation of an unidentified PKC substrate, having a molecular size of 80 kD.



insoluble fraction of P<sub>3</sub> synaptosomes (see above) provided the opportunity to directly test this hypothesis. Synaptosomal cytosolic and 1% TX100-insoluble fractions were co-incubated and the native PKC $\epsilon$  was induced to translocate to the insoluble fraction by adding 1  $\mu$ M 4 $\beta$ -PDBu, in the absence of ATP, to the incubation medium. Insoluble proteins were then sedimented and either assayed directly or first washed three times to remove PDBu (Fig. 4, *inset*). Thus, all subsequent 4 $\beta$ -PDBu-induced phosphotransferase activity in the washed TX100-insoluble fraction could be attributed to the insoluble form of PKC $\epsilon$ . PKC $\epsilon$ -dependent phosphotransferase activity was examined, in the presence of 0.1 mM EGTA, by measuring the autoradiographic densitometric intensity of an endogenous 80-kD phosphoprotein (p80; Fig. 5). Consistent with our working hypothesis, it was observed that the selective targeting of PKC $\epsilon$  to the TX100-insoluble fraction was associated with increased catalytic activity (Fig. 5, lanes 1 and 2). Moreover, this increase in PKC $\epsilon$  phosphotransferase activity was maintained (Fig. 5, lanes 3 and 4) after removing >90% of the bound [<sup>3</sup>H]4 $\beta$ -PDBu (Fig. 4, *inset*).

#### **4 $\beta$ -PDBu Stimulates PKC $\epsilon$ Translocation, PKC $\epsilon$ -dependent Phosphorylation, and Glutamate Exocytosis with Equivalent Potency**

Unless the 4 $\beta$ -PDBu-induced translocation and activation of PKC $\epsilon$  are independent events, 4 $\beta$ -PDBu should stimulate both responses with equal potency. In vitro cosedimentation and phosphorylation assays were performed in the presence of increasing concentrations of 4 $\beta$ -PDBu to compare the EC<sub>50</sub> values for these potentially interdependent responses. The data were analyzed using the equation:  $V = (V_{\max} \times [S]^n) / (EC_{50}^n + [S]^n)$ ; where  $V$  was PKC $\epsilon$  binding, phosphorylation or glutamate exocytosis,  $V_{\max}$  was the maximal  $V$ ,  $n$  was the Hill coefficient,  $[S]$  was the 4 $\beta$ -PDBu concentration employed, and EC<sub>50</sub> was the 4 $\beta$ -PDBu concentration required to achieve  $V_{\max}/2$ . Estimates of the EC<sub>50</sub> values for the 4 $\beta$ -PDBu-dependent translocation of PKC $\epsilon$  in situ (EC<sub>50</sub> = 193 nM) and the in vitro PKC $\epsilon$ -dependent phosphorylation of p80 (EC<sub>50</sub> = 402 nM) did not markedly differ. Moreover, the EC<sub>50</sub> values for these responses were found to be nearly equivalent to that which was calculated from the results of our earlier release experiments (EC<sub>50</sub> = 159 nM; Terrian, 1995). Regression analysis revealed a high degree of correlation between the amount of PKC $\epsilon$  bound and both the PKC $\epsilon$ -dependent phosphorylation of p80 ( $r^2 = 0.737$ ) and Ca<sup>2+</sup>-dependent release of glutamate ( $r^2 = 0.988$ ). These data provide circumstantial evidence that the 4 $\beta$ -PDBu-induced translocation and activation of PKC $\epsilon$  are interdependent events that may represent a necessary prelude to the enhancement of glutamate exocytosis.

#### **Conditions which Prevent the Interaction of PKC $\epsilon$ with the Presynaptic Cytoskeletal Matrix Prevent the 4 $\beta$ -PDBu-dependent Enhancement of Glutamate Exocytosis**


Two independent methods for preventing the 4 $\beta$ -PDBu-dependent enhancement of glutamate exocytosis have been established (Terrian and Ways, 1995). These treatments were used to perform a preliminary analysis of

whether the cytoskeletal localization of PKC $\epsilon$  was essential for the 4 $\beta$ -PDBu-dependent enhancement of glutamate exocytosis. First, intact synaptosomes were pretreated with the PKC inhibitors, sphingosine and staurosporine, before the introduction of either 4 $\alpha$ -PDBu or 4 $\beta$ -PDBu. Synaptosomal suspensions were then used to conduct release and translocation assays in parallel. The presence of inhibitors was maintained throughout all phases of the release assay, since it has been shown previously that continuous inhibition was required to fully prevent the enhancement of glutamate release (Terrian and Ways, 1995). The ability of this treatment to completely abolish the 4 $\beta$ -PDBu-dependent facilitation of glutamate release was confirmed in this experiment (Fig. 6 A). In agreement with predictions that the recruitment of PKC $\epsilon$  to the cytoskeletal matrix was required for the enhancement of glutamate release, sphingosine and staurosporine also blocked the in situ translocation of PKC $\epsilon$  (Fig. 6 A). In a second series of experiments, intact synaptosomes were incubated with cytochalasin D before the addition of PDBu. This treatment has been shown to completely abolish the 4 $\beta$ -PDBu-dependent enhancement of glutamate exocytosis (Terrian and Ways, 1995). Here, it is reported that cytochalasin D also prevented the in situ accumulation of insoluble PKC $\epsilon$  (Fig. 6 B).

#### **4 $\beta$ -PDBu-dependent Interactions of PKC $\epsilon$ with Actin**

The above observations suggest that ionic protein-protein interactions mediate the binding of PKC $\epsilon$  to either filamentous actin itself or to the actin-based skeletal framework of isolated nerve endings. To determine whether PKC $\epsilon$  was anchored in the cytoskeletal matrix by either direct, or indirect, interactions with actin, we used recombinant gelsolin (GS1-406), a highly specific actin filament severing protein (Sun et al., 1994). Based on the known properties of GS1-406, it could be predicted that GS1-406 activity would substantially decrease the average size of actin filaments in synaptosomal TX100-insoluble fractions and, thereby, solubilize proteins that were anchored to this aggregate by the insoluble form of filamentous actin. A portion of the 1% TX100-insoluble fraction was pretreated with GS1-406 and the in vitro binding of PKC $\epsilon$  was stimulated by 4 $\beta$ -PDBu. GS1-406 decreased the amount of insoluble  $\beta$ -actin (data not shown) and PKC $\epsilon$  (Fig. 7 A), providing independent confirmation of the results obtained using cytochalasin D in situ (Fig. 6 B). Overlay assays were next performed in our attempt to identify the PKC $\epsilon$ -binding protein(s). These assays revealed that the synaptosomal 1% TX100-insoluble fraction contained a 43-kD protein that, after denaturation, was capable of binding the native PKC $\epsilon$  in vitro. Interestingly, the mobility of this protein on SDS-PAGE gels precisely matched that of the endogenous  $\beta$ -actin that was present in the same TX100-insoluble fraction (Fig. 7 B). The simplest interpretation of this finding was that PKC $\epsilon$  binds directly to actin. To test this hypothesis, in vitro cosedimentation assays were performed using synaptosomal cytosolic fractions and purified filamentous actin. The data reported that native PKC $\epsilon$  was capable of binding to purified actin filaments, under physiological ionic strength conditions, and that this binding was both saturable and significantly





**Figure 6.** Effect of PKC inhibitors and cytochalasin D on the in situ translocation of PKCε and glutamate exocytosis. (A) Effect of staurosporine and sphingosine on glutamate release and PKCε translocation. Intact synaptosomes were incubated in the absence or presence of staurosporine (1 μM) and sphingosine (100 μM) for 20 min before the introduction of 1 μM 4α-PDBu or 4β-PDBu. After an additional 10 min incubation, aliquots from the same synaptosomal suspension were used to perform parallel superfusion and translocation assays. (B) Effect of cytochalasin D on PKCε translocation. Intact synaptosomes were incubated in the absence or presence of cytochalasin D (1 μM) for 20 min before the introduction of 1 μM 4α-PDBu or 4β-PDBu. Translocation assays were performed after an additional 10-min incubation.


enhanced by the active isoform of PDBu (Fig. 7 C). Neither PKCα nor PKCζ were detected by immunoblot analysis of these same actin pellets (data not shown). Although 4β-PDBu did not alter the affinity of native PKCε for filamentous actin, the  $V_{max}$  was increased almost fourfold (Fig. 7 C). ATP was required to obtain consistent, 4β-PDBu-dependent, binding of PKCε and  $Zn^{2+}$  enhanced this effect (data not shown). At a fixed concentration of purified actin (1 μM) and cytosolic PKCε (41 nM), 4β-PDBu proved to be a potent stimulus for the in vitro association of these native-binding partners (Fig. 7 D;  $EC_{50}$  = 212 nM).

#### Identification of a Putative Actin-binding Motif in PKCε

Sequence motifs that function as recognition signals for protein-protein interactions have previously been identified in competition experiments by coincubating the binding proteins with synthetic peptides that are homologous to the putative binding sites. A series of such experiments indicated that none of the known PKC-binding domains were directly involved in actin binding. Indeed, neither the pseudosubstrate peptide, PKCα<sub>19-31</sub> (10–55 μM) nor annexin I<sub>338-345</sub> (5–20 μM) had any effect on the in vitro binding of native PKCε to actin in the absence or presence of 1 μM 4β-PDBu (data not shown). However, analysis of the PKCε sequence revealed the presence of a motif that had previously been identified as a putative actin-binding mo-

tif in several other actin-binding proteins (Fig. 8 A; Vancompernelle et al., 1991). While this actin-binding motif was found to be conserved in the human, mouse, rat, and rabbit PKCε, it was not present in any other known isoform of PKC, suggesting a mechanism that could account for the selective redistribution of cellular PKCε. Therefore, we examined the ability of a synthetic hexapeptide that corresponded to the putative actin-binding domain of PKCε, PKCε<sub>223-228</sub> (Fig. 8 A), to compete with native PKCε for binding to purified actin and, in a separate experiment, 1% TX100-insoluble synaptosomal fractions. Consistent with the involvement of PKCε<sub>223-228</sub> in the recognition and binding of actin, this hexapeptide (LKKQET) competed, in a dose-dependent manner, with native PKCε for binding to either substrate (Fig. 8 B). Thus, PKCε contains a unique, actin-binding motif that appears to play an important part in the binding of this isoform to actin.

What are the structural determinants for actin binding to PKCε? The fact that PKCε-actin interactions were stimulated by 4β-PDBu indicated that the actin-binding domains in PKCε may normally be hidden when this protein is in an inactive conformation. These contact sites for actin could be integrated into the secondary structure of native PKCε or consist of linear sequences that are complementary to actin (Vandekerckhove and Vancompernelle, 1992). To better understand the requirements for the formation of this complex, equimolar concentrations of denatured, and presumably unfolded, recombinant PKCα, δ, and ε were individually tested for their ability to bind puri-



ing to actin was visualized by immunoblot analysis. Data are the means of the values from three independent experiments. Curve fitting of the resulting values was performed using Sigma Plot Scientific Graphing Software 2.0 (Jandel Scientific Inc.).

fied actin. Significant binding of purified actin to PKCε was observed at a physiological ionic strength and in the absence of PDBu (Fig. 8 C). Actin binding to PKCα or δ was not detected (data not shown), suggesting that PKCε selectively interacted with actin under these conditions. The ability of the synthetic peptide, LKKQET, to effectively compete with recombinant PKCε for actin binding (Fig. 8 C) provided independent support for our previous observations in which cytosol had been used as an alternative source of PKCε (Fig. 8 B). These findings indicated that actin was a PKCε binding protein and that small sequence motifs in the primary structure of PKCε could contain the information that was required for actin recognition and binding.

#### AA and Diacylglycerol Synergistically Interact to Promote the Binding of PKCε to Actin Filaments


While phorbol esters have greatly facilitated investigations into the presynaptic role of PKCε, physiological agonists will ultimately be required for evaluating the potential functional significance of our observations. The triggering events that expose the putative actin-binding domain in PKCε *in vivo* are not known. However, the diacylglycerol and AA that are liberated from membrane phospholipids are widely regarded as putative endogenous signals for PKC activation (Nishizuka, 1992). To determine whether these putative endogenous activators of PKC stimulate the binding of PKCε to purified actin, actin cosedimentation assays were performed using AA as the PKC activator, in the presence and absence of the diacylglycerol analog,

OAG (1 μM). The data were analyzed using the equation:  $V = (V_{max} \times [S]^n) / (EC_{50}^n + [S]^n)$ ; where  $V$  was PKCε binding,  $V_{max}$  was the maximal  $V$ ,  $n$  was the Hill coefficient,  $[S]$  was the AA concentration employed, and  $EC_{50}$  was the AA concentration required to achieve  $V_{max}/2$ . Fig. 9 indicates that AA was a potent stimulus for the binding of PKCε to actin ( $EC_{50} = 10.9 \mu M$ ). The potency of AA was substantially increased ( $EC_{50} = 0.6 \mu M$ ) when OAG, was added to the incubation medium (Fig. 9).


#### Discussion

We have identified a binding site for filamentous actin on PKCε that is unique to this individual isoform of PKC. This actin-binding site was located between the first and second cysteine-rich regions (cys1 and cys2) of the regulatory C1 domain of PKCε, residues 223–228 (Fig. 8 A), in a variety of different species. Although it remains to be determined whether other PKC isoforms have also conserved such unique binding motifs, the existence of PKC<sub>223-228</sub> makes it clear that a mechanism has been established for the pairing of individual PKC isoforms with specific intracellular PKC-binding proteins. This complexity in the control of PKC targeting raises the question of what role these isoform-specific pathways may play in the regulation of cell function. In the case of PKCε, the remarkably stable interaction between PKCε<sub>223-228</sub> and filamentous actin anchors this kinase to the cytoskeletal matrix of presynaptic terminals, where the holoenzyme remains constitutively active and appears to play a primary role in sustaining the

**Figure 7.** Identification of a cytoskeletal PKCε-binding protein. (A) Effect of recombinant gelsolin on the *in vitro* binding of PKCε to native TX100-insoluble components. TX100-insoluble fractions were incubated with recombinant gelsolin (GS1-406) for 1 h, at a protein ratio of 1:5, before reintroducing the native cytosol. Cosedimentation assays were used to measure changes in PKCε binding. (B) Synaptosomal particulate fractions were extracted with 1% TX100 and the insoluble fraction was separated on SDS-PAGE gels, transferred onto nitrocellulose membranes, and overlaid with the native cytosolic fraction. Membranes were then washed and cut in half before probing for either PKCε or β-actin. (C) Cytosolic fractions, containing ~350 ng of native PKCε (50 μg cytosol), were incubated with purified actin in the absence or presence of 1 μM 4β-PDBu. PKCε binding to actin was visualized by immunoblot analysis. Curve fitting of the resulting values was performed using Sigma Plot Scientific Graphing Software 2.0 (Jandel Scientific Inc.). (D) Cytosolic fractions (100 μg) were coincubated with purified actin (10 μg) in the absence (control) or presence of the specified concentration of 4β-PDBu. PKCε binding to actin was visualized by immunoblot analysis. Data are the means of the values from three independent experiments. Curve fitting of the resulting values was performed using Sigma Plot Scientific Graphing Software 2.0 (Jandel Scientific Inc.).



**Figure 8.** A synthetic peptide that is homologous to PKCε<sub>223-228</sub> competes with PKCε for actin binding. (A) Sequence and location of the putative actin-binding domain in PKCε and comparison with the homologous motif in other known actin-binding proteins. (B) Effect of PKCε<sub>223-228</sub> (LKKQET) on the in vitro binding of native PKCε to purified actin and detergent-insoluble synaptosomal components. Polymerized actin (100 μg) or 1% TX100-insoluble fractions (100 μg) were preincubated with 50 μg of synaptosomal cytosol (~350 ng of native PKCε), 1 μM 4β-PDBu, and the specified concentration of PKCε<sub>223-228</sub>, for 30 min before cosedimenting filamentous actin and insoluble PKCε. The efficacy of 4β-PDBu was confirmed in parallel controls that were simultaneously incubated, without PKCε<sub>223-228</sub>, in the presence of 1 μM 4α-PDBu or 4β-PDBu (see inset). (C) Actin binding to recombinant, denatured, PKCε measured by cosedimentation. Human recombinant PKCε (100 ng) was preincubated with purified actin (5 μM) in the absence (lane 2) or presence (lane 3) of the synthetic hexapeptide, LKKQET (80 μM). Lane 1 was a control that contained only polymerized actin. Actin pellets were washed, fractionated by SDS-PAGE, and visualized by immunoblotting with anti-PKCε. The same results were obtained in two independent experiments.



**Figure 9.** Effect of AA and OAG on PKCε binding to purified actin. Actin-binding assays were performed as described in Materials and Methods by coincubating polymerized actin (100 μg) and native PKCε (50 μg cytosol) in the absence or presence of OAG (1 μM) and in the presence of increasing concentrations of AA. Curve fitting was performed on the mean of two (AA alone) or three (AA with OAG) independent determinations, using Sigma Plot Scientific Graphing Software 2.0 (Jandel Scientific, Inc.).

slow phase of glutamate exocytosis. While a surplus of mature synaptic vesicles are typically docked and primed for fusion, the supply of these vesicles must be actively replenished during bouts of high frequency stimulation (Lim et al., 1990). Many details regarding the mechanism that controls membrane recycling and the recruitment of fresh synaptic vesicles remain obscure. A step towards understanding how this mechanism operates is the identification of PKCε as one of the signaling molecules in this complex pathway.

Do other members of the PKC family also participate in the recruitment of endogenous glutamate and long lasting facilitation of exocytosis? This possibility cannot be formally excluded without further investigation. However, the present study provides several observations of direct significance. Endogenous PKCα, β<sub>II</sub>, γ, δ, ε, and ζ were contained in the hippocampal P<sub>3</sub> subcellular fraction. However, the results of our colchicine lesion experiments indicated that only PKCα, ε, and ζ were localized to the hippocampal mossy fiber nerve endings in this synaptosomal preparation. This finding was consistent with electron microscopic observations that PKCε immunoreactivity is located in the hippocampal mossy fiber terminals (Saito et al., 1993), while both PKCβ<sub>II</sub> and γ appear to be excluded from hippocampal nerve endings (Kose et al., 1990). PKCα is principally associated with the Golgi complex of hippocampal neurons (Ito et al., 1990) and little PKCδ immunoreactivity is evident in this brain region (Merchen-thaler et al., 1993). Although PKCζ appeared to be an abundant PKC isoform of mossy fiber origin, translocation assays confirmed that this enzyme does not respond to 4β-PDBu. 4β-PDBu stimulated the in situ translocation of PKCα, β<sub>II</sub>, and γ. However, the association of these PKC isoforms with the particulate fraction was reversed by ei-


ther EGTA (PKC $\beta_{II}$  and  $\gamma$ ) or by removing 4 $\beta$ -PDBu (PKC $\alpha$ ). PKC $\epsilon$  was the only endogenous isoform of PKC to maintain a chelator-resistant interaction with an intracellular protein that could not be dissociated by removing 4 $\beta$ -PDBu. These properties distinguished PKC $\epsilon$  binding from either the Ca<sup>2+</sup>-induced membrane binding, or membrane insertion, of PKC (Bazzi and Nelsestuen, 1988). Thus, multiple isoforms of PKC may contribute to the transient effects of 4 $\beta$ -PDBu on synaptic function, but the long lasting presynaptic effects of 4 $\beta$ -PDBu appeared to be mediated by an isoform-specific pathway. In this regard, it is of interest that the transfection-induced overexpression of PKC $\epsilon$ , but not other PKC isoforms, dramatically increases the secretory activity of pituitary GH<sub>4</sub>C<sub>1</sub> cells (Akita et al., 1994).

Actin filaments are a principal target for activated PKC $\epsilon$  in presynaptic terminals. This conclusion is supported by four independent lines of evidence. First, activated PKC $\epsilon$  remained soluble when intact synaptosomes were pretreated with cytochalasin D and when an aggregate of native, detergent-insoluble, synaptosomal proteins were pretreated with recombinant gelsolin. Second, overlay assays demonstrated that activated PKC $\epsilon$ , but not other isoforms, bound to a detergent-insoluble protein that comigrated with  $\beta$ -actin on SDS-PAGE gels. Third, both native and purified PKC $\epsilon$  bound directly to purified actin. Using cytosolic PKC $\epsilon$ , it was demonstrated that in the absence of PS this binding was dose dependent, saturable, and specific for the PKC $\epsilon$  isoform. Fourth, the binding of either native or recombinant PKC $\epsilon$  to purified actin was effectively inhibited by a synthetic hexapeptide with the sequence of a putative actin-binding domain that is present in the conserved C1 region of PKC $\epsilon$ , PKC $\epsilon_{223-228}$ . Neither PKC $\alpha_{19-31}$  nor annexin I<sub>338-345</sub>, synthetic peptides that have been shown to compete for the binding of other PKC isoforms to anchoring proteins, had any effect on the interaction between PKC $\epsilon$  and actin. PKC $\epsilon$  is the only member of the PKC family to have preserved this actin-binding motif, which is also known to be present in a variety of other actin-binding proteins (Vancompernelle et al., 1991). Thus, while the principle features of the C1 region have been conserved in both the conventional and novel PKC isoforms, individual isoforms may contain variable sequence motifs of functional significance.

The properties of actin binding to PKC $\epsilon$  show that actin filaments represent a new class of PKC-binding protein that has not been revealed by earlier studies. Depending on what cell and PKC activator is used, the various isoforms of PKC will preferentially bind to different intracellular sites within the nucleus (Disatnik et al., 1994), perinuclear region (Staudinger et al., 1995), Golgi network (Lehel et al., 1995), plasma membrane (Bazzi and Nelsestuen, 1988), and cytoskeleton (Wolf and Sahyoun, 1986). Even phorbol esters, which fully activate most of the known PKCs, redistribute the endogenous PKC isoforms of a given cell to different subcellular domains. This indicates that PKC-binding proteins are the principal determinants of targeting specificity, since activated PKC can only associate with those microdomains that are capable of recognizing and binding these enzymes (Mochly-Rosen, 1995). In contrast to the RACKs (Mochly-Rosen et al., 1991; Ron et al., 1994) and other PKC-binding proteins (Chapline et

al., 1993; Liao et al., 1994) that have been identified, filamentous actin bound directly to activated PKC $\epsilon$ , in the absence of PS. Actin is also clearly distinguished from the recently described PICK proteins (Staudinger et al., 1995) by the fact that PICKs interact with the catalytic domain of PKC, whereas actin seems to bind the regulatory domain of PKC $\epsilon$ . An *in vitro* study has indicated that PKC $\beta$  and  $\gamma$  may also be capable of interacting with actin, in a PS-dependent manner (Zalewski et al., 1991). However, many PKC isoforms that interact with lipid vesicles and purified proteins in *in vitro* systems do not associate with these receptors in the intact cell (Szallasi et al., 1994). Our assays of PKC binding have demonstrated that PKC $\epsilon$  was the only endogenous isoform of PKC that directly interacted with purified actin in the absence of PS. Moreover, it has been shown that PKC $\epsilon$  tightly binds to actin filaments in the intact nerve terminal. Thus, actin appears to be a novel PKC-binding protein that displays distinct and isoform-specific requirements for physiological binding.

Actin binding stimulates a persistent increase in constitutive PKC $\epsilon$  activity. The discovery that the insoluble form of PKC $\epsilon$  could be isolated from all other endogenous isoforms of PKC provided an opportunity to examine the effect of actin binding on the Ca<sup>2+</sup>-independent activity of this novel PKC isoform. It is concluded that neither proteolytic activation nor irreversible insertion can account for the increased PKC $\epsilon$  activity that was observed in the present study. Proteolytic cleavage of PKC $\epsilon$  produces an effector-independent increase in phosphotransferase activity (Schaap et al., 1990). While the carboxyl terminal catalytic fragment of PKC $\epsilon$  that is generated by limited proteolysis has been shown to bind nonneuronal intermediate filaments, it does not bind to actin (Omary et al., 1992). As actin filaments were the principal binding protein for PKC $\epsilon$  in the synaptosomal preparation, this catalytic fragment would not be expected to cosediment with the washed detergent-insoluble aggregate to which the full-length PKC $\epsilon$  was bound. Moreover, it may be concluded that the constitutive activation of PKC $\epsilon$  did not result from hydrophobic interactions of this kinase with a lipid bilayer. This would be consistent with the observations that bound PKC $\epsilon$  could not be solubilized by high concentrations of either TX100 or octyl glucoside and that the *in vitro* PKC $\epsilon$  binding and phosphotransferase activity were unaffected by phospholipids, such as PS. Whether autophosphorylation was responsible for the persistent activation of PKC $\epsilon$  is unknown. The available evidence indicates that the activity of PKC $\epsilon$  may be influenced by an intramolecular or intermolecular form of kinase activity (Koide et al., 1992; Saido et al., 1992). Studies are in progress to determine whether dephosphorylation alters the constitutive phosphotransferase activity of actin-bound PKC $\epsilon$ . However, the simplest possibility is that activators of PKC $\epsilon$  simultaneously produce an allosteric activation of the enzyme and expose a cryptic binding sequence for actin filaments (Fig. 10). This implies that a transient increase in PKC $\epsilon$  activity could be maintained, in the absence of stimulatory cofactors and indifferent to changes in PKC $\epsilon$  phosphorylation, for several hours by the ability of actin filaments to tightly bind and activate PKC $\epsilon$ . The model in Fig. 10 provides a basis for our findings and identifies a PKC $\epsilon$  binding and activating protein, whose



**Figure 10.** Model for the assembly and constitutive activation of a PKCε-specific signaling complex. Binding of an activator, such as arachidonic acid/diacylglycerol, would be required to simultaneously promote the allosteric activation of PKCε and to expose a cryptic binding site for the cytoskeletal protein, actin (step 1). The anchoring of PKCε to actin (step 2) does not require, but is associated with, increased phosphotransferase activity. Metabolism of the endogenous activator for PKCε would result in the reversal of some actin binding and the resolubilization of inactive PKCε (step 3). However, a pool of the PKCε that remains tightly bound to actin continues to be catalytically active in the absence of the agonist that initially targeted this PKC isoform into the cytoskeletal matrix (step 4). Reversible and stable binding of PKCε to this protein may be preferentially induced by partial and complete agonists, respectively. This model suggests that actin represents a bifunctional, chaperone and anchoring protein that is specific for the PKCε isoform. The assembly and stabilization of this actin-PKCε complex appears to play a primary role in the PKC-dependent enhancement of sustained glutamate exocytosis (step 5).

tion of inactive PKCε (step 3). However, a pool of the PKCε that remains tightly bound to actin continues to be catalytically active in the absence of the agonist that initially targeted this PKC isoform into the cytoskeletal matrix (step 4). Reversible and stable binding of PKCε to this protein may be preferentially induced by partial and complete agonists, respectively. This model suggests that actin represents a bifunctional, chaperone and anchoring protein that is specific for the PKCε isoform. The assembly and stabilization of this actin-PKCε complex appears to play a primary role in the PKC-dependent enhancement of sustained glutamate exocytosis (step 5).

existence was first suggested by Parker and colleagues (Pears et al., 1991). Such a mechanism would assign an additional level of functional significance to bifunctional PKC-anchoring proteins that are capable of maintaining PKCs in a catalytically active conformation.

PKCε binding to purified actin was synergistically stimulated by AA and the diacylglycerol analog, OAG. The presence of PKCε in the TX100-insoluble fraction of freshly isolated synaptosomes indicated that the enzyme had been physiologically activated in these terminals. Candidate signals for PKCε activation included AA and diacylglycerol, because these two lipid metabolites had previously been shown to increase PKCε-dependent phosphotransferase activity (Koide et al., 1992; Kasahara and Kikkawa, 1995) and the evoked release of endogenous glutamate (Zhang and Dorman, 1993). The present results are in agreement with the hypothesis that AA is a potent endogenous activator of PKCε, while PS effectively activates PKCα, β, γ, and δ, but not PKCε (Kasahara and Kikkawa, 1995). In the absence of either  $Ca^{2+}$  or PS, AA significantly increased the binding of PKCε to filamentous actin. Although OAG by itself had no effect on the binding of actin by PKCε, the addition of OAG when AA was present caused a synergistic enhancement of PKCε binding. A similar interaction results in the potentiation of glutamate release from synaptosomal preparations (Zhang and Dorman, 1993). In this preparation, the stimulation of metabotropic glutamate receptors effectively mimics the permissive effect of OAG on AA-induced release (Herrero et al., 1992). Thus, phospholipid metabolism may well participate in the physiological activation of PKCε and this mechanism seems to be closely regulated. Optimal activation appears to be contingent upon the coactivation of presynaptic metabotropic glutamate receptors, for the production of diacylglycerol and phospholipase  $A_2$ , for the liberation of AA (Nishizuka, 1992). Both conditions are likely to be satisfied during the bouts of intense presynaptic activity that

produce a long lasting increase in neurotransmitter release (Schulz et al., 1994).

Formal and direct proof that a causal relationship exists between the actin binding of PKCε, the constitutive activation of this kinase, and the enhancement of glutamate release will require further investigation. However, it is possible to estimate the likelihood that these response data sets represent interdependent events by comparing their individual  $EC_{50}$  values for 4β-PDBu. As the ratio of these  $EC_{50}$  values approach unity there is a corresponding increase in the confidence that such a relationship exists. The result of such an analysis estimated that there is a reasonably high (>95%) probability that the translocation of PKCε, PKCε binding to actin, and the enhancement of glutamate exocytosis were functionally related. These results, together with the demonstration that treatments which prevent PKCε binding and activation also abolish the enhancement of glutamate release by 4β-PDBu, are in agreement with the suggestion that the extent to which phorbol esters facilitate the slow phase of glutamate exocytosis may be influenced by the binding of PKCε to actin.

The present results suggest that the individual isoforms of PKC may have assumed distinct responsibilities for the control of regulated secretion. In the case of PKCε, we have discovered that this specificity could have been achieved through the conservation of an actin-binding motif in this, but not in other PKC isoforms. The existence of this distinct binding site in PKCε explains how this isoform becomes specifically paired with, and tightly bound to, actin filaments in the presynaptic cytoskeletal matrix. Use-dependent changes in lipid metabolism have been shown to be capable of generating the endogenous signals that are required to expose this actin-binding site in native PKCε. Once bound to actin, PKCε remained constitutively active in the absence of lipid metabolites or membrane phospholipids. Thus, actin not only appears to be a novel and specific PKCε-binding protein, but may also act as an

agonist that is capable of maintaining this kinase in a catalytically active conformation for several hours (Fig. 10). The assembly of this isoform-specific signaling complex may have multiple and diverse influences on synaptic function. The present results, together with our previous studies, indicate that one outcome of functional significance may be the enhanced availability of synaptic vesicles for exocytosis during intense bouts of presynaptic activity.

We wish to thank D. K. Ways for the generous gift of anti-PKC isoform-specific antisera, J. M. Chalovich for purified actin, and H. L. Yin for the recombinant gelsolin that was used in this study. We also thank C. M. Manning and G. G. Wescott for their expert technical assistance. We are grateful to D. K. Ways, J. E. deVente, and P. H. Pekala for critical review of the manuscript.

This study was supported by National Science Foundation grant IBN-93-12414 (D. M. Terrian).

Received for publication 24 April 1995 and in revised form 19 October 1995.

## References

- Akita, Y., S. Ohno, Y. Yajima, Y. Konno, T. C. Saido, K. Mizuno, K. Chida, S. Osada, T. Kuroki, S. Kawashima, et al. 1994. Overproduction of a  $\text{Ca}^{2+}$ -independent protein kinase C isozyme, nPKC $\epsilon$ , increases the secretion of prolactin from thyrotropin-releasing hormone-stimulated rat pituitary GH $_4\text{C}_1$  cells. *J. Biol. Chem.* 269:4653–4660.
- Bazzi, M. D., and G. L. Nelsestuen. 1988. Properties of membrane-inserted protein kinase C. *Biochemistry*. 27:7589–7593.
- Brown, D. A., and J. K. Rose. 1992. Sorting of GPI-anchored proteins to glycolipid-enriched membrane subdomains during transport to the apical cell surface. *Cell*. 68:533–544.
- Chapline, C., K. Ramsay, T. Klauk, and S. Jaken. 1993. Interaction cloning of protein kinase C substrates. *J. Biol. Chem.* 268:6858–6861.
- Conner-Kerr, T. A., D. R. Simmons, G. M. Peterson, and D. M. Terrian. 1993. Evidence for the corelease of dynorphin and glutamate from rat hippocampal mossy fiber terminals. *J. Neurochem.* 61:627–636.
- Dekker, L. V., and P. J. Parker. 1994. Protein kinase C—a question of specificity. *TIBS*. 19:73–77.
- Disatnik, M. H., G. Buraggi, and D. Mochly-Rosen. 1994. Localisation of protein kinase C isozymes in cardiac myocytes. *Exp. Cell Res.* 210:287–297.
- Fey, E. G., K. M. Wan, and S. Penman. 1984. Epithelial cytoskeletal framework and nuclear matrix-intermediate filament scaffold: three-dimensional organization and protein composition. *J. Cell Biol.* 98:1973–1984.
- Herrero, I., M. T. Miras-Portugal, and J. Sanchez-Prieto. 1992. Positive feedback of glutamate exocytosis by metabotropic presynaptic receptor stimulation. *Nature (Lond.)*. 360:163–165.
- Huang, Y.-Y., P. A. Colley, and A. Routtenberg. 1992. Postsynaptic then presynaptic protein kinase C activity may be necessary for long-term potentiation. *Neuroscience*. 49:819–827.
- Hug, H., and T. F. Sarre. 1993. Protein kinase C isoenzymes: divergence in signal transduction? *Biochem. J.* 291:329–343.
- Ito, A., N. Saito, M. Hirata, A. Kose, T. Tsujino, C. Yoshihara, K. Ogita, A. Kishimoto, Y. Nishizuka, and C. Tanaka. 1990. Immunocytochemical localization of the  $\alpha$  subtypes of protein kinase C in rat brain. *Proc. Natl. Acad. Sci. USA*. 87:3195–3199.
- Kasahara, K., and U. Kikkawa. 1995. Distinct effects of saturated fatty acids on protein kinase C subtypes. *J. Biochem.* 117:648–653.
- Kazanietz, M. G., K. W. Krausz, and P. M. Blumberg. 1992. Differential irreversible insertion of protein kinase C into phospholipid vesicles by phorbol esters and related activators. *J. Biol. Chem.* 267:20878–20886.
- Kiley, S. C., P. J. Parker, D. Fabbro, and S. Jaken. 1992. Selective redistribution of protein kinase C isozymes by thapsigargin and staurosporine. *Carcinogenesis*. 13:1997–2001.
- Koide, H., K. Ogita, U. Kikkawa, and Y. Nishizuka. 1992. Isolation and characterization of the subtypes of protein kinase C from rat brain. *Proc. Natl. Acad. Sci. USA*. 89:1149–1153.
- Kose, A., A. Ito, N. Saito, and C. Tanaka. 1990. Electron microscopic localization of  $\gamma$ - and  $\beta\text{II}$ -subtypes of protein kinase C in rat hippocampus. *Brain Res.* 518:209–217.
- Lehel, C., Z. Olah, G. Jakab, Z. Szallasi, G. Petrovics, G. Harta, P. Blumberg, and W. B. Anderson. 1995. Protein kinase C  $\epsilon$  subcellular localization domains and proteolytic degradation sites. *J. Biol. Chem.* 270:19651–19658.
- Liao, L., S. L. Hyatt, C. Chapline, and S. Jaken. 1994. Protein kinase C domains involved in interactions with other proteins. *Biochemistry*. 33:1229–1233.
- Lim, N. F., M. C. Nowycky, and R. J. Bookman. 1990. Direct measurement of exocytosis and calcium currents in single vertebrate nerve terminals. *Nature (Lond.)*. 344:449–481.
- Madison, D. V., R. C. Malenka, and R. A. Nicoll. 1991. Mechanisms underlying long-term potentiation of synaptic transmission. *Annu. Rev. Neurosci.* 14:379–397.
- Merchenthaler, I., Z. Liposits, J. J. Reid, and W. C. Wetsel. 1993. Light and electron microscopic immunocytochemical localization of PKC $\delta$  immunoreactivity in the rat central nervous system. *J. Comp. Neurol.* 336:378–399.
- Mochly-Rosen, D. 1995. Localization of protein kinases by anchoring proteins: a theme in signal transduction. *Science (Wash. DC)*. 268:247–251.
- Mochly-Rosen, D., H. Khaner, and J. Lopez. 1991. Identification of intracellular receptor protein for activated protein kinase C. *Proc. Natl. Acad. Sci. USA*. 88:3997–4000.
- Nishizuka, Y. 1992. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. *Science (Wash. DC)*. 258:607–614.
- Omary, M. B., G. T. Baxter, C. F. Chou, W. Y. Lin, and B. Strulovici. 1992. PKC $\epsilon$ -related kinase associates with and phosphorylates cytokeratin 8 and 18. *J. Cell Biol.* 117:583–593.
- Pears, C., D. Schaap, and P. J. Parker. 1991. The regulatory domain of protein kinase C- $\epsilon$  restricts the catalytic-domain-specificity. *Biochem. J.* 276:257–260.
- Ron, D., C. H. Chen, J. Caldwell, L. Jamieson, E. Orr, and D. Mochly-Rosen. 1994. Cloning of an intracellular receptor for protein kinase C: a homolog of the  $\beta$  subunit of G proteins. *Proc. Natl. Acad. Sci. USA*. 91:839–843.
- Saido, T. C., K. Mizuno, Y. Konno, S. I. Osada, S. Ohno, and K. Suzuki. 1992. Purification and characterization of protein kinase C $\epsilon$  from rabbit brain. *Biochemistry*. 31:482–490.
- Saito, N., A. Itouji, Y. Totani, I. Osawa, H. Koide, N. Fujisawa, K. Ogita, and C. Tanaka. 1993. Cellular and intracellular localisation of  $\epsilon$ -subtypes of protein kinase C in the rat brain; presynaptic localization of the  $\epsilon$ -subtypes. *Brain Res.* 607:241–248.
- Schaap, D., J. Hsuan, N. Totty, and P. J. Parker. 1990. Proteolytic activation of protein kinase C- $\epsilon$ . *Eur. J. Biochem.* 191:431–435.
- Schulz, P. E., E. P. Cook, and D. Johnston. 1994. Changes in paired-pulse facilitation suggests presynaptic involvement in long-term potentiation. *J. Neurosci.* 14:5325–5337.
- Staudinger, F., J. Zhou, R. Burgess, S. J. Elledge, and E. N. Olson. 1995. PICK1: a perinuclear protein and substrate for protein kinase C isolated by the yeast two-hybrid system. *J. Cell Biol.* 128:263–270.
- Stevens, C. F., and Y. Wang. 1994. Changes in reliability of synaptic function as a mechanism for plasticity. *Nature (Lond.)*. 371:704–707.
- Sublette, E., M. U. Naik, X. Jiang, P. Osten, H. Valsamis, S. I. Osada, S. Ohno, and T. C. Sacktor. 1993. Evidence for a new, high-molecular weight isoform of protein kinase C in rat hippocampus. *Neurosci. Lett.* 159:175–178.
- Sun, H. Q., D. C. Wooten, P. A. Janmey, and H. L. Yin. 1994. The actin side-binding domain of gelsolin also caps actin filaments. *J. Biol. Chem.* 269:9473–9479.
- Szallasi, Z., C. B. Smith, and P. M. Blumberg. 1994. Dissociation of phorbol esters leads to immediate redistribution to the cytosol of protein kinases Ca and C $\delta$  in mouse keratinocytes. *J. Biol. Chem.* 269:27159–27162.
- Terrian, D. M. 1995. Persistent enhancement of sustained calcium-dependent glutamate release by phorbol esters: requirement for localized calcium entry. *J. Neurochem.* 64:172–180.
- Terrian, D. M., and D. K. Ways. 1995. Persistent enhancement of sustained calcium-dependent glutamate release by phorbol esters: role of calmodulin-independent serine/threonine phosphorylation and actin disassembly. *J. Neurochem.* 64:181–190.
- Terrian, D. M., D. Johnston, B. J. Claiborne, R. Ansah-Yiadom, W. J. Strittmatter, and M. A. Rea. 1988. Glutamate and dynorphin release from a subcellular fraction enriched in hippocampal mossy fiber synaptosomes. *Brain Res. Bull.* 21:343–351.
- Terrian, D. M., D. K. Ways, and R. L. Gannon. 1991. A presynaptic role for protein kinase C in hippocampal mossy fiber synaptic transmission. *Hippocampus*. 1:303–314.
- Terrian, D. M., D. K. Ways, R. L. Gannon, and D. A. Zetts. 1993. Transduction of protein kinase C-generated signal into the long-lasting facilitation of glutamate release. *Hippocampus*. 3:205–220.
- Vancompernelle, K., J. Vandekerckhove, M. R. Bubb, and E. D. Korn. 1991. The interfaces of actin and Acanthamoeba Actobindin. *J. Biol. Chem.* 266:15427–15431.
- Vandekerckhove, J., and K. Vancompernelle. 1992. Structural relationships of actin-binding proteins. *Curr. Opin. Cell Biol.* 4:36–42.
- Ways, K., R. Riddle, M. Ways, and P. Cook. 1991. Effect of phorbol esters on cytosolic protein kinase C content and activity in the human monoblastoid U937 cell. *J. Biol. Chem.* 266:1258–1264.
- Wolf, M., and N. Sahyoun. 1986. Protein kinase C and phosphatidylserine bind to M $_1$  110,000/115,000 polypeptides enriched in cytoskeletal and postsynaptic density. *J. Biol. Chem.* 261:13327–13332.
- Yamamoto, C., M. Higashima, and S. Sawada. 1987. Quantal analysis of potentiating action of phorbol ester on synaptic transmission in the hippocampus. *Neurosci. Res.* 5:28–38.
- Zalewski, P. D., I. J. Forbes, C. Giannakis, and W. H. Betts. 1991. Regulation of protein kinase C by  $\text{Zn}^{2+}$ -dependent interaction with actin. *Biochem. Intl.* 24:1103–1110.
- Zhang, L., and R. V. Dorman. 1993. Synergistic potentiation of glutamate release by arachidonic acid and oleoyl-acetyl-glycerol. *Brain Res. Bull.* 32:437–441.